Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04334759 · ClinicalTrials.gov registry record · Phase 3
DuRvalumab With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma
A Phase 3 study, sponsored by PrECOG.
- Completed
- Registry status
- Phase 3
- Development phase
- 214
- Enrollment target
NCT04334759 is a Phase 3 study that has completed, run by PrECOG. The registered enrollment target is 214 participants.
The verdict
NCT04334759, a Phase 3 study, has completed, sponsored by PrECOG.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 214 participants
- Enrollment target
Study Summary
Patients with pleural mesothelioma (PM) that cannot be surgically removed will receive standard chemotherapy (cisplatin or carboplatin and pemetrexed) given with durvalumab, a type of immunotherapy, or a treatment chosen by the study doctor, which is either standard chemotherapy or immunotherapy combination (ipilimumab and nivolumab). Durvalumab is an antibody (a type of human protein) that works by blocking a body substance called Programmed Death-Ligand 1 (PD-L1). Blocking PD-L1 helps the body's immune system attack cancer cells. Research has shown that durvalumab can slow tumor growth and shrink tumors in some people with cancer. Previous studies of combining durvalumab and chemotherapy showed that this combination is active in advanced mesothelioma. The purpose of this study is to see whether adding durvalumab to standard chemotherapy will improve overall survival (OS) in patients with PM.
Interventions
- DRUG Durvalumab
- DRUG Standard Chemotherapy
- DRUG Ipilimumab and Nivolumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 214 participants |
| Start Date | 2021-02-18 |
| Est. Completion | 2025-06-30 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04334759
The ClinicalTrials.gov registry entry for NCT04334759 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 214 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is PrECOG, which has 17 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Durvalumab is the first listed.
NCT04334759 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04334759 about?
NCT04334759 is a clinical study titled "DuRvalumab With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma". Patients with pleural mesothelioma (PM) that cannot be surgically removed will receive standard chemotherapy (cisplatin or carboplatin and pemetrexed) given with durvalumab, a type of immunotherapy, or a treatment chosen by the study doctor, which is either standard chemotherapy or immunotherapy com...
What is the current status of trial NCT04334759?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 214 participants. The study started on 2021-02-18. Estimated completion is 2025-06-30.
What interventions are being tested in trial NCT04334759?
The interventions under investigation include: Durvalumab (DRUG), Standard Chemotherapy (DRUG), Ipilimumab and Nivolumab (DRUG).
Who is sponsoring clinical trial NCT04334759?
This trial is sponsored by PrECOG, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.